-
1
-
-
78649237682
-
Women survive breast cancer but fall victim to heart failure: The shadows and lights of targeted therapy
-
Maurea N, Coppola C, Ragone G, Frasci G, Bonelli A, Romano C, et al. Women survive breast cancer but fall victim to heart failure: The shadows and lights of targeted therapy. J Cardiovasc Med (Hagerstown) 2010; 11(12): 861-8.
-
(2010)
J Cardiovasc Med (Hagerstown)
, vol.11
, Issue.12
, pp. 861-868
-
-
Maurea, N.1
Coppola, C.2
Ragone, G.3
Frasci, G.4
Bonelli, A.5
Romano, C.6
-
2
-
-
77954394371
-
A phase I/II study of neoadjuvant liposomal doxorubicin, paclitaxel, and hyperthermia in locally advanced breast cancer
-
Vujaskovic Z, Kim DW, Jones E, Lan L, McCall L, Dewhirst MW, et al. A phase I/II study of neoadjuvant liposomal doxorubicin, paclitaxel, and hyperthermia in locally advanced breast cancer. Int J Hyperthermia 2010; 26(5): 514-21.
-
(2010)
Int J Hyperthermia
, vol.26
, Issue.5
, pp. 514-521
-
-
Vujaskovic, Z.1
Kim, D.W.2
Jones, E.3
Lan, L.4
McCall, L.5
Dewhirst, M.W.6
-
3
-
-
38949174220
-
Capecitabine-related cardiotoxicity: Recognition and management
-
Saif MW, Tomita M, Ledbetter L, Diasio RB. Capecitabine-related cardiotoxicity: Recognition and management. J Support Oncol 2008; 6(1): 41-8.
-
(2008)
J Support Oncol
, vol.6
, Issue.1
, pp. 41-48
-
-
Saif, M.W.1
Tomita, M.2
Ledbetter, L.3
Diasio, R.B.4
-
4
-
-
62449193617
-
Docetaxel With cyclophosphamide is associated with an overall survival benefit compared with doxorubicin and cyclophosphamide: 7-Year follow-up of us oncology research trial 9735
-
Jones S, Holmes FA, O'Shaughnessy J, Blum JL, Vukelja SJ, McIntyre KJ, et al. Docetaxel With cyclophosphamide is associated with an overall survival benefit compared with doxorubicin and cyclophosphamide: 7-Year follow-up of us oncology research trial 9735. J Clin Oncol 2009; 27(8): 1177-83.
-
(2009)
J Clin Oncol
, vol.27
, Issue.8
, pp. 1177-1183
-
-
Jones, S.1
Holmes, F.A.2
O'Shaughnessy, J.3
Blum, J.L.4
Vukelja, S.J.5
McIntyre, K.J.6
-
5
-
-
84856223809
-
Dual HER2-targeted approaches in HER2-positive breast cancer
-
Ahn ER, Vogel CL. Dual HER2-targeted approaches in HER2-positive breast cancer. Breast Cancer Res Treat 2012; 131(2): 371-83.
-
(2012)
Breast Cancer Res Treat
, vol.131
, Issue.2
, pp. 371-383
-
-
Ahn, E.R.1
Vogel, C.L.2
-
6
-
-
0033907078
-
Emerging antibody-based HER2 (ErbB-2/neu) therapeutics
-
Krauss WC, Park JW, Kirpotin DB, Hong K, Benz CC. Emerging antibody-based HER2 (ErbB-2/neu) therapeutics. Breast Dis 2000; 11: 113-24.
-
(2000)
Breast Dis
, vol.11
, pp. 113-124
-
-
Krauss, W.C.1
Park, J.W.2
Kirpotin, D.B.3
Hong, K.4
Benz, C.C.5
-
7
-
-
77950142741
-
Nanoparticle-mediated cytoplasmic delivery of proteins to target cellular machinery
-
Bale SS, Kwon SJ, Shah DA, Banerjee A, Dordick JS, Kane RS. Nanoparticle-mediated cytoplasmic delivery of proteins to target cellular machinery. ACS Nano 2010; 4(3): 1493-500.
-
(2010)
ACS Nano
, vol.4
, Issue.3
, pp. 1493-1500
-
-
Bale, S.S.1
Kwon, S.J.2
Shah, D.A.3
Banerjee, A.4
Dordick, J.S.5
Kane, R.S.6
-
8
-
-
77956292811
-
The role of HER2 in cancer therapy and targeted drug delivery
-
Tai W, Mahato R, Cheng K. The role of HER2 in cancer therapy and targeted drug delivery. J Control Release 2010; 146(3): 264-75.
-
(2010)
J Control Release
, vol.146
, Issue.3
, pp. 264-275
-
-
Tai, W.1
Mahato, R.2
Cheng, K.3
-
9
-
-
0035874981
-
Trastuzumab (herceptin), a humanized anti-HER2 receptor monoclonal antibody, inhibits basal and activated HER2 ectodomain cleavage in breast cancer cells
-
Molina MA, Codony-Servat J, Albanell J, Rojo F, Arribas J, Baselga J. Trastuzumab (herceptin), a humanized anti-HER2 receptor monoclonal antibody, inhibits basal and activated HER2 ectodomain cleavage in breast cancer cells. Cancer Res 2001; 61(12): 4744-9.
-
(2001)
Cancer Res
, vol.61
, Issue.12
, pp. 4744-4749
-
-
Molina, M.A.1
Codony-Servat, J.2
Albanell, J.3
Rojo, F.4
Arribas, J.5
Baselga, J.6
-
10
-
-
34249317254
-
HER-2 overexpression increases the metastatic outgrowth of breast cancer cells in the brain
-
Palmieri D, Bronder JL, Herring JM, Yoneda T, Weil RJ, Stark AM, et al. HER-2 overexpression increases the metastatic outgrowth of breast cancer cells in the brain. Cancer Res 2007; 67(9): 4190-8.
-
(2007)
Cancer Res
, vol.67
, Issue.9
, pp. 4190-4198
-
-
Palmieri, D.1
Bronder, J.L.2
Herring, J.M.3
Yoneda, T.4
Weil, R.J.5
Stark, A.M.6
-
11
-
-
75449089516
-
Beyond trastuzumab: Small molecule tyrosine kinase inhibitors in HER-2-positive breast cancer
-
Roy V, Perez EA. Beyond trastuzumab: small molecule tyrosine kinase inhibitors in HER-2-positive breast cancer. Oncologist 2009; 14(11): 1061-9.
-
(2009)
Oncologist
, vol.14
, Issue.11
, pp. 1061-1069
-
-
Roy, V.1
Perez, E.A.2
-
12
-
-
79952631264
-
Rational use of trastuzumab in metastatic and locally advanced breast cancer: Implications of recent research
-
Goel S, Chirgwin J, Francis P, Stuart-Harris R, Dewar J, Mileshkin L, et al. Rational use of trastuzumab in metastatic and locally advanced breast cancer: Implications of recent research. Breast 2011; 20(2): 101-10.
-
(2011)
Breast
, vol.20
, Issue.2
, pp. 101-110
-
-
Goel, S.1
Chirgwin, J.2
Francis, P.3
Stuart-Harris, R.4
Dewar, J.5
Mileshkin, L.6
-
13
-
-
0036498781
-
Cardiac dysfunction in the trastuzumab clinical trials experience
-
Seidman A, Hudis C, Pierri MK, Shak S, Paton V, Ashby M, et al. Cardiac dysfunction in the trastuzumab clinical trials experience. J Clin Oncol 2002; 20(5): 1215-21.
-
(2002)
J Clin Oncol
, vol.20
, Issue.5
, pp. 1215-1221
-
-
Seidman, A.1
Hudis, C.2
Pierri, M.K.3
Shak, S.4
Paton, V.5
Ashby, M.6
-
14
-
-
77951058617
-
Trastuzumab-based therapy for patients with HER2-positive breast cancer: From early scientific development to foundation of care
-
Brufsky A. Trastuzumab-based therapy for patients with HER2-positive breast cancer: From early scientific development to foundation of care. Am J Clin Oncol 2010; 33(2): 186-95.
-
(2010)
Am J Clin Oncol
, vol.33
, Issue.2
, pp. 186-195
-
-
Brufsky, A.1
-
15
-
-
84864619911
-
Anti-HER2 single-chain antibody mediated DNMTs-siRNA delivery for targeted breast cancer therapy
-
Dou S, Yao YD, Yang XZ, Sun TM, Mao CQ, Song EW, et al. Anti-HER2 single-chain antibody mediated DNMTs-siRNA delivery for targeted breast cancer therapy. J Control Release 2012; 161(3): 875-83.
-
(2012)
J Control Release
, vol.161
, Issue.3
, pp. 875-883
-
-
Dou, S.1
Yao, Y.D.2
Yang, X.Z.3
Sun, T.M.4
Mao, C.Q.5
Song, E.W.6
-
16
-
-
33644695614
-
Pulmonary toxicity from novel antineoplastic agents
-
Dimopoulou I, Bamias A, Lyberopoulos P, Dimopoulos MA. Pulmonary toxicity from novel antineoplastic agents. Ann Oncol 2006; 17(3): 372-9.
-
(2006)
Ann Oncol
, vol.17
, Issue.3
, pp. 372-379
-
-
Dimopoulou, I.1
Bamias, A.2
Lyberopoulos, P.3
Dimopoulos, M.A.4
-
18
-
-
0035874887
-
High affinity restricts the localization and tumor penetration of single-chain fv antibody molecules
-
Adams GP, Schier R, McCall AM, Simmons HH, Horak EM, Alpaugh RK, et al. High affinity restricts the localization and tumor penetration of single-chain fv antibody molecules. Cancer Res 2001; 61(12): 4750-5.
-
(2001)
Cancer Res
, vol.61
, Issue.12
, pp. 4750-4755
-
-
Adams, G.P.1
Schier, R.2
McCall, A.M.3
Simmons, H.H.4
Horak, E.M.5
Alpaugh, R.K.6
-
20
-
-
72649087326
-
Estrogen action: A historic perspective on the implications of considering alternative approaches
-
Jensen EV, Jacobson HI, Walf AA, Frye CA. Estrogen action: A historic perspective on the implications of considering alternative approaches. Physiol Behav 2010; 99(2): 151-62.
-
(2010)
Physiol Behav
, vol.99
, Issue.2
, pp. 151-162
-
-
Jensen, E.V.1
Jacobson, H.I.2
Walf, A.A.3
Frye, C.A.4
-
23
-
-
76749091057
-
Activity of fulvestrant 500 mg versus anastrozole 1 mg as first-line treatment for advanced breast cancer: Results from the FIRST study
-
Robertson JF, Llombart-Cussac A, Rolski J, Feltl D, Dewar J, Macpherson E, et al. Activity of fulvestrant 500 mg versus anastrozole 1 mg as first-line treatment for advanced breast cancer: results from the FIRST study. J Clin Oncol 2009; 27(27): 4530-5.
-
(2009)
J Clin Oncol
, vol.27
, Issue.27
, pp. 4530-4535
-
-
Robertson, J.F.1
Llombart-Cussac, A.2
Rolski, J.3
Feltl, D.4
Dewar, J.5
McPherson, E.6
-
28
-
-
84863617400
-
Promising therapeutic options in triple-negative breast cancer
-
Bilici A, Arslan C, Altundag K. Promising therapeutic options in triple-negative breast cancer. J Buon 2012; 17(2): 209-22.
-
(2012)
J Buon
, vol.17
, Issue.2
, pp. 209-222
-
-
Bilici, A.1
Arslan, C.2
Altundag, K.3
-
29
-
-
74049105681
-
WNT signaling enhances breast cancer cell motility and blockade of the WNT pathway by sFRP1 suppresses MDA-MB-231 xenograft growth
-
Matsuda Y, Schlange T, Oakeley EJ, Boulay A, Hynes NE. WNT signaling enhances breast cancer cell motility and blockade of the WNT pathway by sFRP1 suppresses MDA-MB-231 xenograft growth. Breast Cancer Res 2009; 11(3): R32.
-
(2009)
Breast Cancer Res
, vol.11
, Issue.3
-
-
Matsuda, Y.1
Schlange, T.2
Oakeley, E.J.3
Boulay, A.4
Hynes, N.E.5
-
30
-
-
70349332814
-
Current data of targeted therapies for the treatment of triple-negative advanced breast cancer: Empiricism or evidence-based?
-
Petrelli F, Cabiddu M, Ghilardi M, Barni S. Current data of targeted therapies for the treatment of triple-negative advanced breast cancer: Empiricism or evidence-based? Expert Opin Investig Drugs 2009; 18(10): 1467-77.
-
(2009)
Expert Opin Investig Drugs
, vol.18
, Issue.10
, pp. 1467-1477
-
-
Petrelli, F.1
Cabiddu, M.2
Ghilardi, M.3
Barni, S.4
-
31
-
-
84892572211
-
Efficacy and safety of docetaxel combined with oxaliplatin as a neoadjuvant chemotherapy regimen for Chinese triple-negative local advanced breast cancer patients: A prospective, open, and unicentric phase II clinical trial
-
[Epub ahead of print]
-
Fei F, Chen C, Xue J, Di GH, Lu JS, Liu GY, et al. Efficacy and safety of docetaxel combined with oxaliplatin as a neoadjuvant chemotherapy regimen for Chinese triple-negative local advanced breast cancer patients: A prospective, open, and unicentric phase II clinical trial. Am J Clin Oncol 2012. [Epub ahead of print].
-
(2012)
Am J Clin Oncol
-
-
Fei, F.1
Chen, C.2
Xue, J.3
Di, G.H.4
Lu, J.S.5
Liu, G.Y.6
-
32
-
-
79952261244
-
EGFR-homing dsRNA activates cancer-targeted immune response and eliminates disseminated EGFR-overexpressing tumors in mice
-
Shir A, Ogris M, Roedl W, Wagner E, Levitzki A. EGFR-homing dsRNA activates cancer-targeted immune response and eliminates disseminated EGFR-overexpressing tumors in mice. Clin Cancer Res 2011; 17(5): 1033-43.
-
(2011)
Clin Cancer Res
, vol.17
, Issue.5
, pp. 1033-1043
-
-
Shir, A.1
Ogris, M.2
Roedl, W.3
Wagner, E.4
Levitzki, A.5
-
34
-
-
23144464171
-
Cancer/testis antigens, gametogenesis and cancer
-
Simpson AJ, Caballero OL, Jungbluth A, Chen YT, Old LJ. Cancer/testis antigens, gametogenesis and cancer. Nat Rev Cancer 2005; 5(8): 615-25.
-
(2005)
Nat Rev Cancer
, vol.5
, Issue.8
, pp. 615-625
-
-
Simpson, A.J.1
Caballero, O.L.2
Jungbluth, A.3
Chen, Y.T.4
Old, L.J.5
-
35
-
-
69449084128
-
CT-X antigen expression in human breast cancer
-
Grigoriadis A, Caballero OL, Hoek KS, da Silva L, Chen YT, Shin SJ, et al. CT-X antigen expression in human breast cancer. Proc Natl Acad Sci USA 2009; 106(32): 13493-8.
-
(2009)
Proc Natl Acad Sci USA
, vol.106
, Issue.32
, pp. 13493-13498
-
-
Grigoriadis, A.1
Caballero, O.L.2
Hoek, K.S.3
da Silva, L.4
Chen, Y.T.5
Shin, S.J.6
-
36
-
-
79952785519
-
Multiple cancer/testis antigens are preferentially expressed in hormone-receptor negative and high-grade breast cancers
-
Chen YT, Ross DS, Chiu R, Zhou XK, Chen YY, Lee P, et al. Multiple cancer/testis antigens are preferentially expressed in hormone-receptor negative and high-grade breast cancers. PLoS One 2011; 6(3): e17876.
-
(2011)
PLoS One
, vol.6
, Issue.3
-
-
Chen, Y.T.1
Ross, D.S.2
Chiu, R.3
Zhou, X.K.4
Chen, Y.Y.5
Lee, P.6
-
37
-
-
84905659064
-
-
US20100010072
-
Dmitrovsky, E., Liu, X., Freemantle, S., Sempere, L., Cole, C., Kauppinen, S., Bak, M., Christensen, M. MicroRNA biomarkers for human breast and lung cancer. US20100010072 (2010).
-
(2010)
MicroRNA biomarkers for human breast and lung cancer
-
-
Dmitrovsky, E.1
Liu, X.2
Freemantle, S.3
Sempere, L.4
Cole, C.5
Kauppinen, S.6
Bak, M.7
Christensen, M.8
-
38
-
-
84858703841
-
The miR-200 and miR-221/222 microRNA families: Opposing effects on epithelial identity
-
Howe EN, Cochrane DR, Richer JK. The miR-200 and miR-221/222 microRNA families: Opposing effects on epithelial identity. J Mammary Gland Biol Neoplasia 2012; 17(1): 65-77.
-
(2012)
J Mammary Gland Biol Neoplasia
, vol.17
, Issue.1
, pp. 65-77
-
-
Howe, E.N.1
Cochrane, D.R.2
Richer, J.K.3
-
40
-
-
80052314150
-
Implication of miRNA in the diagnosis and treatment of breast cancer
-
Castaneda CA, Agullo-Ortuno MT, Fresno Vara JA, Cortes-Funes H, Gomez HL, Ciruelos E. Implication of miRNA in the diagnosis and treatment of breast cancer. Expert Rev Anticancer Ther 2011; 11(8): 1265-75.
-
(2011)
Expert Rev Anticancer Ther
, vol.11
, Issue.8
, pp. 1265-1275
-
-
Castaneda, C.A.1
Agullo-Ortuno, M.T.2
Fresno Vara, J.A.3
Cortes-Funes, H.4
Gomez, H.L.5
Ciruelos, E.6
-
41
-
-
84875290480
-
-
WO2012075533
-
Iyer, K.L., Evans, C.W., Clemons, T.D., Fitzgerald, M., Dunlop, S.A., Luzinov, I., Zdyrko, B. Multifunctional nanoparticles. WO2012075533 (2012).
-
(2012)
Multifunctional nanoparticles
-
-
Iyer, K.L.1
Evans, C.W.2
Clemons, T.D.3
Fitzgerald, M.4
Dunlop, S.A.5
Luzinov, I.6
Zdyrko, B.7
-
42
-
-
84866269413
-
Triple negative breast cancer: A brief review of its characteristics and treatment options
-
Griffiths CL, Olin JL. Triple negative breast cancer: A brief review of its characteristics and treatment options. J Pharm Pract 2012; 25(3): 319-23.
-
(2012)
J Pharm Pract
, vol.25
, Issue.3
, pp. 319-323
-
-
Griffiths, C.L.1
Olin, J.L.2
-
43
-
-
84858975438
-
Poly (ADP-ribose) polymerase (PARP): Rationale, preclinical and clinical evidences of its inhibition as breast cancer treatment
-
Orlando L, Schiavone P, Fedele P, Calvani N, Nacci A, Cinefra M, et al. Poly (ADP-ribose) polymerase (PARP): Rationale, preclinical and clinical evidences of its inhibition as breast cancer treatment. Expert Opin Ther Targets 2012; 16 (Suppl 2): S83-9.
-
(2012)
Expert Opin Ther Targets
, vol.16
, Issue.SUPPL. 2
-
-
Orlando, L.1
Schiavone, P.2
Fedele, P.3
Calvani, N.4
Nacci, A.5
Cinefra, M.6
-
44
-
-
84861676580
-
Triple-negative breast cancer and poly(ADP-ribose) polymerase inhibitors
-
Park Y, Moriyama A, Kitahara T, Yoshida Y, Urita T, Kato R. Triple-negative breast cancer and poly(ADP-ribose) polymerase inhibitors. Anticancer Agents Med Chem 2012; 12(6): 672-7.
-
(2012)
Anticancer Agents Med Chem
, vol.12
, Issue.6
, pp. 672-677
-
-
Park, Y.1
Moriyama, A.2
Kitahara, T.3
Yoshida, Y.4
Urita, T.5
Kato, R.6
-
45
-
-
84856889082
-
The potential for poly (ADP-ribose) polymerase inhibitors in cancer therapy
-
Javle M, Curtin NJ. The potential for poly (ADP-ribose) polymerase inhibitors in cancer therapy. Ther Adv Med Oncol 2011; 3(6): 257-67.
-
(2011)
Ther Adv Med Oncol
, vol.3
, Issue.6
, pp. 257-267
-
-
Javle, M.1
Curtin, N.J.2
-
46
-
-
83355172188
-
PAX2 is activated by estradiol in breast cancer cells of the luminal subgroup selectively, to confer a low invasive phenotype
-
Beauchemin D, Lacombe C, Van Themsche C. PAX2 is activated by estradiol in breast cancer cells of the luminal subgroup selectively, to confer a low invasive phenotype. Mol Cancer 2011; 10: 148.
-
(2011)
Mol Cancer
, vol.10
, pp. 148
-
-
Beauchemin, D.1
Lacombe, C.2
van Themsche, C.3
-
47
-
-
34848838572
-
Functional analysis of the host defense peptide Human Beta Defensin-1: New insight into its potential role in cancer
-
Bullard RS, Gibson W, Bose SK, Belgrave JK, Eaddy AC, Wright CJ, et al. Functional analysis of the host defense peptide Human Beta Defensin-1: New insight into its potential role in cancer. Mol Immunol 2008; 45(3): 839-48.
-
(2008)
Mol Immunol
, vol.45
, Issue.3
, pp. 839-848
-
-
Bullard, R.S.1
Gibson, W.2
Bose, S.K.3
Belgrave, J.K.4
Eaddy, A.C.5
Wright, C.J.6
-
48
-
-
60949110142
-
PAX2 oncogene negatively regulates the expression of the host defense peptide human beta defensin-1 in prostate cancer
-
Bose SK, Gibson W, Bullard RS, Donald CD. PAX2 oncogene negatively regulates the expression of the host defense peptide human beta defensin-1 in prostate cancer. Mol Immunol 2009; 46(6): 1140-8.
-
(2009)
Mol Immunol
, vol.46
, Issue.6
, pp. 1140-1148
-
-
Bose, S.K.1
Gibson, W.2
Bullard, R.S.3
Donald, C.D.4
-
51
-
-
57349113761
-
Regulation of ERBB2 by oestrogen receptor-PAX2 determines response to tamoxifen
-
Hurtado A, Holmes KA, Geistlinger TR, Hutcheson IR, Nicholson RI, Brown M, et al. Regulation of ERBB2 by oestrogen receptor-PAX2 determines response to tamoxifen. Nature 2008; 456(7222): 663-6.
-
(2008)
Nature
, vol.456
, Issue.7222
, pp. 663-666
-
-
Hurtado, A.1
Holmes, K.A.2
Geistlinger, T.R.3
Hutcheson, I.R.4
Nicholson, R.I.5
Brown, M.6
-
52
-
-
84863727766
-
Vascular proliferation is a prognostic factor in breast cancer
-
Arnes JB, Stefansson IM, Straume O, Baak JP, Lonning PE, Foulkes WD, et al. Vascular proliferation is a prognostic factor in breast cancer. Breast Cancer Res Treat 2012; 133(2): 501-10.
-
(2012)
Breast Cancer Res Treat
, vol.133
, Issue.2
, pp. 501-510
-
-
Arnes, J.B.1
Stefansson, I.M.2
Straume, O.3
Baak, J.P.4
Lonning, P.E.5
Foulkes, W.D.6
-
53
-
-
82255191709
-
Vascular proliferation is increased in basal-like breast cancer
-
Nalwoga H, Arnes JB, Stefansson IM, Wabinga H, Foulkes WD, Akslen LA. Vascular proliferation is increased in basal-like breast cancer. Breast Cancer Res Treat 2011; 130(3): 1063-71.
-
(2011)
Breast Cancer Res Treat
, vol.130
, Issue.3
, pp. 1063-1071
-
-
Nalwoga, H.1
Arnes, J.B.2
Stefansson, I.M.3
Wabinga, H.4
Foulkes, W.D.5
Akslen, L.A.6
-
54
-
-
84875346936
-
-
WO2012054717
-
Vogelstein, B., Qiao, Y., Huang, X., Kinzler, K., Zhou, S., Diaz, L. Detecting and treating solid tumors through selective disruption of tumor vasculature. WO2012054717 (2012).
-
(2012)
Detecting and treating solid tumors through selective disruption of tumor vasculature
-
-
Vogelstein, B.1
Qiao, Y.2
Huang, X.3
Kinzler, K.4
Zhou, S.5
Diaz, L.6
-
58
-
-
84875339141
-
-
US20120202801
-
Cao, L., Davis, T.W., Hirawat, S., Miao, H.H., Miller, L., Romfo, C.M., Weetall, M.L. Methods for treating breast cancer. US20120202801 (2012).
-
(2012)
Methods for treating breast cancer
-
-
Cao, L.1
Davis, T.W.2
Hirawat, S.3
Miao, H.H.4
Miller, L.5
Romfo, C.M.6
Weetall, M.L.7
-
60
-
-
0242468884
-
A phase I/II dose-escalation trial of bevacizumab in previously treated metastatic breast cancer
-
Cobleigh MA, Langmuir VK, Sledge GW, Miller KD, Haney L, Novotny WF, et al. A phase I/II dose-escalation trial of bevacizumab in previously treated metastatic breast cancer. Semin Oncol 2003; 30(5 Suppl 16): 117-24.
-
(2003)
Semin Oncol
, vol.30
, Issue.5 SUPPL. 16
, pp. 117-124
-
-
Cobleigh, M.A.1
Langmuir, V.K.2
Sledge, G.W.3
Miller, K.D.4
Haney, L.5
Novotny, W.F.6
-
61
-
-
0026485002
-
Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis
-
Shweiki D, Itin A, Soffer D, Keshet E. Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis. Nature 1992; 359(6398): 843-5.
-
(1992)
Nature
, vol.359
, Issue.6398
, pp. 843-845
-
-
Shweiki, D.1
Itin, A.2
Soffer, D.3
Keshet, E.4
-
62
-
-
34547124062
-
Hypoxia: A key regulator of angiogenesis in cancer
-
Liao D, Johnson RS. Hypoxia: A key regulator of angiogenesis in cancer. Cancer Metastasis Rev 2007; 26(2): 281-90.
-
(2007)
Cancer Metastasis Rev
, vol.26
, Issue.2
, pp. 281-290
-
-
Liao, D.1
Johnson, R.S.2
-
63
-
-
70350002279
-
Adverse effects of anticancer agents that target the VEGF pathway
-
Chen HX, Cleck JN. Adverse effects of anticancer agents that target the VEGF pathway. Nat Rev Clin Oncol 2009; 6(8): 465-77.
-
(2009)
Nat Rev Clin Oncol
, vol.6
, Issue.8
, pp. 465-477
-
-
Chen, H.X.1
Cleck, J.N.2
-
64
-
-
77954668887
-
Angiogenesis inhibitors: Current strategies and future prospects
-
Cook KM, Figg WD. Angiogenesis inhibitors: Current strategies and future prospects. CA Cancer J Clin 2010; 60(4): 222-43.
-
(2010)
CA Cancer J Clin
, vol.60
, Issue.4
, pp. 222-243
-
-
Cook, K.M.1
Figg, W.D.2
-
65
-
-
84869465976
-
North Central Cancer Treatment Group (NCCTG) N0537: Phase II trial of VEGF-Trap in patients with metastatic breast cancer previously treated with an anthracycline and/or a taxane
-
Sideras K, Dueck AC, Hobday TJ, Rowland KM, Jr., Allred JB, Northfelt DW, et al. North Central Cancer Treatment Group (NCCTG) N0537: Phase II trial of VEGF-Trap in patients with metastatic breast cancer previously treated with an anthracycline and/or a taxane. Clin Breast Cancer 2012; 12(6): 387-91.
-
(2012)
Clin Breast Cancer
, vol.12
, Issue.6
, pp. 387-391
-
-
Sideras, K.1
Dueck, A.C.2
Hobday, T.J.3
Rowland Jr., K.M.4
Allred, J.B.5
Northfelt, D.W.6
-
70
-
-
77952399799
-
Phase II study on the addition of ASA404 (vadimezan; 5,6-dimethylxanthenone-4-acetic acid) to docetaxel in CRMPC
-
Pili R, Rosenthal MA, Mainwaring PN, Van Hazel G, Srinivas S, Dreicer R, et al. Phase II study on the addition of ASA404 (vadimezan; 5,6-dimethylxanthenone-4-acetic acid) to docetaxel in CRMPC. Clin Cancer Res 2010; 16(10): 2906-14.
-
(2010)
Clin Cancer Res
, vol.16
, Issue.10
, pp. 2906-2914
-
-
Pili, R.1
Rosenthal, M.A.2
Mainwaring, P.N.3
van Hazel, G.4
Srinivas, S.5
Dreicer, R.6
-
71
-
-
84875319053
-
-
US20110052575
-
Baca, M., Wells, J.A., Presta, L.G., Lowman, H.B., Chen, Y.M. Anti-VEGF antibodies. US20110052575 (2010).
-
(2010)
Anti-VEGF antibodies
-
-
Baca, M.1
Wells, J.A.2
Presta, L.G.3
Lowman, H.B.4
Chen, Y.M.5
-
73
-
-
84875352232
-
-
WO2010058426
-
Murali, K.A., Bharat, K., Shailaja, C. Inhibition of VEGF-A secretion, angiogenesis and/or neoangiogenesis by sina mediated knockdown of VEGF-C and Rhoa. WO2010058426 (2010).
-
(2010)
Inhibition of VEGF-A secretion, angiogenesis and/or neoangiogenesis by sina mediated knockdown of VEGF-C and Rhoa
-
-
Murali, K.A.1
Bharat, K.2
Shailaja, C.3
-
74
-
-
84875281797
-
-
WO2012028716
-
Gschwind, A., Borges, E., Boucneau, J., DE Tavernier, E., Kolkman, J., Merchiers, P. VEGF-binding molecules. WO2012028716 (2012).
-
(2012)
VEGF-binding molecules
-
-
Gschwind, A.1
Borges, E.2
Boucneau, J.3
de Tavernier, E.4
Kolkman, J.5
Merchiers, P.6
-
75
-
-
33750812269
-
Angiogenesis-associated protein annexin II in breast cancer: Selective expression in invasive breast cancer and contribution to tumor invasion and progression
-
Sharma MR, Koltowski L, Ownbey RT, Tuszynski GP, Sharma MC. Angiogenesis-associated protein annexin II in breast cancer: Selective expression in invasive breast cancer and contribution to tumor invasion and progression. Exp Mol Pathol 2006; 81(2): 146-56.
-
(2006)
Exp Mol Pathol
, vol.81
, Issue.2
, pp. 146-156
-
-
Sharma, M.R.1
Koltowski, L.2
Ownbey, R.T.3
Tuszynski, G.P.4
Sharma, M.C.5
-
76
-
-
0029670206
-
p16INK4A as a human tumor suppressor
-
Shapiro GI, Rollins BJ. p16INK4A as a human tumor suppressor. Biochim Biophys Acta 1996; 1242(3): 165-9.
-
(1996)
Biochim Biophys Acta
, vol.1242
, Issue.3
, pp. 165-169
-
-
Shapiro, G.I.1
Rollins, B.J.2
-
77
-
-
84875333898
-
Inhibition of breast tumor cell growth by ectopic expression of p16/INK4A via combined effects of cell cycle arrest, senescence and apoptotic induction, and angiogenesis inhibition
-
Lu Y, Zhang X, Zhang J. Inhibition of breast tumor cell growth by ectopic expression of p16/INK4A via combined effects of cell cycle arrest, senescence and apoptotic induction, and angiogenesis inhibition. J Cancer 2012; 3: 333-44.
-
(2012)
J Cancer
, vol.3
, pp. 333-344
-
-
Lu, Y.1
Zhang, X.2
Zhang, J.3
-
78
-
-
84868195812
-
Ellagic acid, a phenolic compound, exerts anti-angiogenesis effects via VEGFR-2 signaling pathway in breast cancer
-
Wang N, Wang ZY, Mo SL, Loo TY, Wang DM, Luo HB, et al. Ellagic acid, a phenolic compound, exerts anti-angiogenesis effects via VEGFR-2 signaling pathway in breast cancer. Breast Cancer Res Treat 2012; 134(3): 943-55.
-
(2012)
Breast Cancer Res Treat
, vol.134
, Issue.3
, pp. 943-955
-
-
Wang, N.1
Wang, Z.Y.2
Mo, S.L.3
Loo, T.Y.4
Wang, D.M.5
Luo, H.B.6
-
79
-
-
84867771909
-
CCL2/CCR2 Chemokine signaling coordinates survival and motility of breast cancer cells through Smad3 protein-and p42/44 Mitogen-activated Protein Kinase (MAPK)-dependent mechanisms
-
Fang WB, Jokar I, Zou A, Lambert D, Dendukuri P, Cheng N. CCL2/CCR2 Chemokine signaling coordinates survival and motility of breast cancer cells through Smad3 protein-and p42/44 Mitogen-activated Protein Kinase (MAPK)-dependent mechanisms. J Biol Chem 2012; 287(43): 36593-608.
-
(2012)
J Biol Chem
, vol.287
, Issue.43
, pp. 36593-36608
-
-
Fang, W.B.1
Jokar, I.2
Zou, A.3
Lambert, D.4
Dendukuri, P.5
Cheng, N.6
-
80
-
-
84867563621
-
Importance of chemokine (CC-motif) ligand 2 in breast cancer
-
Steiner JL, Murphy EA. Importance of chemokine (CC-motif) ligand 2 in breast cancer. Int J Biol Markers 2012; 27(3): e179-85.
-
(2012)
Int J Biol Markers
, vol.27
, Issue.3
-
-
Steiner, J.L.1
Murphy, E.A.2
-
81
-
-
84863724938
-
Targeting monocyte chemotactic protein-1 synthesis with bindarit induces tumor regression in prostate and breast cancer animal models
-
Zollo M, Di Dato V, Spano D, De Martino D, Liguori L, Marino N, et al. Targeting monocyte chemotactic protein-1 synthesis with bindarit induces tumor regression in prostate and breast cancer animal models. Clin Exp Metastasis 2012; 29(6): 585-601.
-
(2012)
Clin Exp Metastasis
, vol.29
, Issue.6
, pp. 585-601
-
-
Zollo, M.1
Di Dato, V.2
Spano, D.3
de Martino, D.4
Liguori, L.5
Marino, N.6
-
82
-
-
84859715721
-
Tumor microenvironment: A main actor in the metastasis process
-
Spano D, Zollo M. Tumor microenvironment: A main actor in the metastasis process. Clin Exp Metastasis 2012; 29(4): 381-95.
-
(2012)
Clin Exp Metastasis
, vol.29
, Issue.4
, pp. 381-395
-
-
Spano, D.1
Zollo, M.2
-
85
-
-
0034800309
-
Heterogeneity of proteinkinase C activity and PKCzeta expression in clinical breast carcinomas
-
Schondorf T, Kurbacher CM, Becker M, Warm M, Kolhagen H, Gohring UJ. Heterogeneity of proteinkinase C activity and PKCzeta expression in clinical breast carcinomas. Clin Exp Med 2001; 1(1): 1-8.
-
(2001)
Clin Exp Med
, vol.1
, Issue.1
, pp. 1-8
-
-
Schondorf, T.1
Kurbacher, C.M.2
Becker, M.3
Warm, M.4
Kolhagen, H.5
Gohring, U.J.6
-
87
-
-
36749015683
-
Cannabidiol as a novel inhibitor of Id-1 gene expression in aggressive breast cancer cells
-
McAllister SD, Christian RT, Horowitz MP, Garcia A, Desprez PY. Cannabidiol as a novel inhibitor of Id-1 gene expression in aggressive breast cancer cells. Mol Cancer Ther 2007; 6(11): 2921-7.
-
(2007)
Mol Cancer Ther
, vol.6
, Issue.11
, pp. 2921-2927
-
-
McAllister, S.D.1
Christian, R.T.2
Horowitz, M.P.3
Garcia, A.4
Desprez, P.Y.5
-
89
-
-
84859409756
-
Antitumor activity of a novel bispecific antibody that targets the ErbB2/ErbB3 oncogenic unit and inhibits heregulininduced activation of ErbB3
-
McDonagh CF, Huhalov A, Harms BD, Adams S, Paragas V, Oyama S, et al. Antitumor activity of a novel bispecific antibody that targets the ErbB2/ErbB3 oncogenic unit and inhibits heregulininduced activation of ErbB3. Mol Cancer Ther 2012; 11(3): 582-93.
-
(2012)
Mol Cancer Ther
, vol.11
, Issue.3
, pp. 582-593
-
-
McDonagh, C.F.1
Huhalov, A.2
Harms, B.D.3
Adams, S.4
Paragas, V.5
Oyama, S.6
-
91
-
-
84859985179
-
The multifactorial role of leptin in driving the breast cancer microenvironment
-
Ando S, Catalano S. The multifactorial role of leptin in driving the breast cancer microenvironment. Nat Rev Endocrinol 2012; 8(5): 263-75.
-
(2012)
Nat Rev Endocrinol
, vol.8
, Issue.5
, pp. 263-275
-
-
Ando, S.1
Catalano, S.2
-
95
-
-
84868460976
-
Inhibition of leptin gene expression and secretion by silibinin: Possible role of estrogen receptors
-
Nejati-Koshki K, Zarghami N, Pourhassan-Moghaddam M, Rahmati-Yamchi M, Mollazade M, Nasiri M, et al. Inhibition of leptin gene expression and secretion by silibinin: Possible role of estrogen receptors. Cytotechnology 2012; 64(6): 719-26.
-
(2012)
Cytotechnology
, vol.64
, Issue.6
, pp. 719-726
-
-
Nejati-Koshki, K.1
Zarghami, N.2
Pourhassan-Moghaddam, M.3
Rahmati-Yamchi, M.4
Mollazade, M.5
Nasiri, M.6
-
96
-
-
77949566512
-
Leptin as a potential therapeutic target for breast cancer prevention and treatment
-
Ray A, Cleary MP. Leptin as a potential therapeutic target for breast cancer prevention and treatment. Expert Opin Ther Targets 2010; 14(4): 443-51.
-
(2010)
Expert Opin Ther Targets
, vol.14
, Issue.4
, pp. 443-451
-
-
Ray, A.1
Cleary, M.P.2
-
97
-
-
34248157798
-
Obesity hormone leptin: A new target in breast cancer?
-
Surmacz E. Obesity hormone leptin: A new target in breast cancer? Breast Cancer Res 2007; 9(1): 301.
-
(2007)
Breast Cancer Res
, vol.9
, Issue.1
, pp. 301
-
-
Surmacz, E.1
-
99
-
-
84875291844
-
-
US20130005668
-
Raitano, A.B., Jakobovits, A., Challita-eid, P.M., Kanner, S.B., Ge, W., Perez-villar, J.J., Morrison, R.K. Nucleic acids and corresponding proteins entitled 158P3D2 useful in treatment and detection of cancer. US20130005668 (2013).
-
(2013)
Nucleic acids and corresponding proteins entitled 158P3D2 useful in treatment and detection of cancer
-
-
Raitano, A.B.1
Jakobovits, A.2
Challita-eid, P.M.3
Kanner, S.B.4
Ge, W.5
Perez-villar, J.J.6
Morrison, R.K.7
-
101
-
-
70349501666
-
Treatment of inflammatory diseases with mesenchymal stem cells
-
Newman RE, Yoo D, LeRoux MA, Danilkovitch-Miagkova A. Treatment of inflammatory diseases with mesenchymal stem cells. Inflamm Allergy Drug Targets 2009;8(2): 110-23.
-
(2009)
Inflamm Allergy Drug Targets
, vol.8
, Issue.2
, pp. 110-123
-
-
Newman, R.E.1
Yoo, D.2
LeRoux, M.A.3
Danilkovitch-Miagkova, A.4
-
102
-
-
77951444290
-
Time-dependent migration of systemically delivered bone marrow mesenchymal stem cells to the infarcted heart
-
Assis AC, Carvalho JL, Jacoby BA, Ferreira RL, Castanheira P, Diniz SO, et al. Time-dependent migration of systemically delivered bone marrow mesenchymal stem cells to the infarcted heart. Cell Transplant 2010; 19(2): 219-30.
-
(2010)
Cell Transplant
, vol.19
, Issue.2
, pp. 219-230
-
-
Assis, A.C.1
Carvalho, J.L.2
Jacoby, B.A.3
Ferreira, R.L.4
Castanheira, P.5
Diniz, S.O.6
-
103
-
-
34547763362
-
Exogenous mesenchymal stem cells localize to the kidney by means of CD44 following acute tubular injury
-
Herrera MB, Bussolati B, Bruno S, Morando L, Mauriello-Romanazzi G, Sanavio F, et al. Exogenous mesenchymal stem cells localize to the kidney by means of CD44 following acute tubular injury. Kidney Int 2007; 72(4): 430-41.
-
(2007)
Kidney Int
, vol.72
, Issue.4
, pp. 430-441
-
-
Herrera, M.B.1
Bussolati, B.2
Bruno, S.3
Morando, L.4
Mauriello-Romanazzi, G.5
Sanavio, F.6
-
104
-
-
33751252831
-
Adult bone-marrowderived mesenchymal stem cells contribute to wound healing of skin appendages
-
Li H, Fu X, Ouyang Y, Cai C, Wang J, Sun T. Adult bone-marrowderived mesenchymal stem cells contribute to wound healing of skin appendages. Cell Tissue Res 2006; 326(3): 725-36.
-
(2006)
Cell Tissue Res
, vol.326
, Issue.3
, pp. 725-736
-
-
Li, H.1
Fu, X.2
Ouyang, Y.3
Cai, C.4
Wang, J.5
Sun, T.6
-
105
-
-
77952805220
-
Human mesenchymal stem cells and their use in cell-based therapies
-
Motaln H, Schichor C, Lah TT. Human mesenchymal stem cells and their use in cell-based therapies. Cancer 2010; 116(11): 2519-30.
-
(2010)
Cancer
, vol.116
, Issue.11
, pp. 2519-2530
-
-
Motaln, H.1
Schichor, C.2
Lah, T.T.3
-
106
-
-
77951753751
-
Chemokines mediate mesenchymal stem cell migration toward gliomas in vitro
-
Xu F, Shi J, Yu B, Ni W, Wu X, Gu Z. Chemokines mediate mesenchymal stem cell migration toward gliomas in vitro. Oncol Rep 2010; 23(6): 1561-7.
-
(2010)
Oncol Rep
, vol.23
, Issue.6
, pp. 1561-1567
-
-
Xu, F.1
Shi, J.2
Yu, B.3
Ni, W.4
Wu, X.5
Gu, Z.6
-
107
-
-
66249083525
-
Mesenchymal stem cell delivery of TRAIL can eliminate metastatic cancer
-
Loebinger MR, Eddaoudi A, Davies D, Janes SM. Mesenchymal stem cell delivery of TRAIL can eliminate metastatic cancer. Cancer Res 2009; 69(10): 4134-42.
-
(2009)
Cancer Res
, vol.69
, Issue.10
, pp. 4134-4142
-
-
Loebinger, M.R.1
Eddaoudi, A.2
Davies, D.3
Janes, S.M.4
-
108
-
-
71549114206
-
Magnetic resonance imaging of mesenchymal stem cells homing to pulmonary metastases using biocompatible magnetic nanoparticles
-
Loebinger MR, Kyrtatos PG, Turmaine M, Price AN, Pankhurst Q, Lythgoe MF, et al. Magnetic resonance imaging of mesenchymal stem cells homing to pulmonary metastases using biocompatible magnetic nanoparticles. Cancer Res 2009; 69(23): 8862-7.
-
(2009)
Cancer Res
, vol.69
, Issue.23
, pp. 8862-8867
-
-
Loebinger, M.R.1
Kyrtatos, P.G.2
Turmaine, M.3
Price, A.N.4
Pankhurst, Q.5
Lythgoe, M.F.6
-
109
-
-
43049139914
-
Inflammation and tumor microenvironments: Defining the migratory itinerary of mesenchymal stem cells
-
Spaeth E, Klopp A, Dembinski J, Andreeff M, Marini F. Inflammation and tumor microenvironments: Defining the migratory itinerary of mesenchymal stem cells. Gene Ther 2008; 15(10): 730-8.
-
(2008)
Gene Ther
, vol.15
, Issue.10
, pp. 730-738
-
-
Spaeth, E.1
Klopp, A.2
Dembinski, J.3
Andreeff, M.4
Marini, F.5
-
110
-
-
41149159755
-
A tumorselective biotherapy with prolonged impact on established metastases based on cytokine gene-engineered MSCs
-
Chen X, Lin X, Zhao J, Shi W, Zhang H, Wang Y, et al. A tumorselective biotherapy with prolonged impact on established metastases based on cytokine gene-engineered MSCs. Mol Ther 2008; 16(4): 749-56.
-
(2008)
Mol Ther
, vol.16
, Issue.4
, pp. 749-756
-
-
Chen, X.1
Lin, X.2
Zhao, J.3
Shi, W.4
Zhang, H.5
Wang, Y.6
-
111
-
-
37549036588
-
Tumor irradiation increases the recruitment of circulating mesenchymal stem cells into the tumor microenvironment
-
Klopp AH, Spaeth EL, Dembinski JL, Woodward WA, Munshi A, Meyn RE, et al. Tumor irradiation increases the recruitment of circulating mesenchymal stem cells into the tumor microenvironment. Cancer Res 2007; 67(24): 11687-95.
-
(2007)
Cancer Res
, vol.67
, Issue.24
, pp. 11687-11695
-
-
Klopp, A.H.1
Spaeth, E.L.2
Dembinski, J.L.3
Woodward, W.A.4
Munshi, A.5
Meyn, R.E.6
-
112
-
-
70349515175
-
Radiation increases invasion of gene-modified mesenchymal stem cells into tumors
-
Zielske SP, Livant DL, Lawrence TS. Radiation increases invasion of gene-modified mesenchymal stem cells into tumors. Int J Radiat Oncol Biol Phys 2009; 75(3): 843-53.
-
(2009)
Int J Radiat Oncol Biol Phys
, vol.75
, Issue.3
, pp. 843-853
-
-
Zielske, S.P.1
Livant, D.L.2
Lawrence, T.S.3
-
113
-
-
84867680330
-
Stem cell implants for cancer therapy: TRAILexpressing mesenchymal stem cells target cancer cells in situ
-
Reagan MR, Seib FP, McMillin DW, Sage EK, Mitsiades CS, Janes SM, et al. Stem cell implants for cancer therapy: TRAILexpressing mesenchymal stem cells target cancer cells in situ. J Breast Cancer 2012; 15(3): 273-82.
-
(2012)
J Breast Cancer
, vol.15
, Issue.3
, pp. 273-282
-
-
Reagan, M.R.1
Seib, F.P.2
McMillin, D.W.3
Sage, E.K.4
Mitsiades, C.S.5
Janes, S.M.6
-
114
-
-
84860639631
-
Mesenchymal stem cells engineered for cancer therapy
-
Shah K. Mesenchymal stem cells engineered for cancer therapy. Adv Drug Deliv Rev 2012; 64(8): 739-48.
-
(2012)
Adv Drug Deliv Rev
, vol.64
, Issue.8
, pp. 739-748
-
-
Shah, K.1
-
115
-
-
78249275567
-
Mesenchymal stem cells at the intersection of cell and gene therapy
-
Myers TJ, Granero-Molto F, Longobardi L, Li T, Yan Y, Spagnoli A. Mesenchymal stem cells at the intersection of cell and gene therapy. Expert Opin Biol Ther 2010; 10(12): 1663-79.
-
(2010)
Expert Opin Biol Ther
, vol.10
, Issue.12
, pp. 1663-1679
-
-
Myers, T.J.1
Granero-Molto, F.2
Longobardi, L.3
Li, T.4
Yan, Y.5
Spagnoli, A.6
-
116
-
-
84860513584
-
The bad and the good of mesenchymal stem cells in cancer: Boosters of tumor growth and vehicles for targeted delivery of anticancer agents
-
Galderisi U, Giordano A, Paggi MG. The bad and the good of mesenchymal stem cells in cancer: Boosters of tumor growth and vehicles for targeted delivery of anticancer agents. World J Stem Cells 2010; 2(1): 5-12.
-
(2010)
World J Stem Cells
, vol.2
, Issue.1
, pp. 5-12
-
-
Galderisi, U.1
Giordano, A.2
Paggi, M.G.3
-
117
-
-
43049088843
-
Stem and progenitor cellmediated tumor selective gene therapy
-
Aboody KS, Najbauer J, Danks MK. Stem and progenitor cellmediated tumor selective gene therapy. Gene Ther 2008; 15(10): 739-52.
-
(2008)
Gene Ther
, vol.15
, Issue.10
, pp. 739-752
-
-
Aboody, K.S.1
Najbauer, J.2
Danks, M.K.3
-
118
-
-
57749089644
-
Neural stem cell tropism to glioma: Critical role of tumor hypoxia
-
Zhao D, Najbauer J, Garcia E, Metz MZ, Gutova M, Glackin CA, et al. Neural stem cell tropism to glioma: Critical role of tumor hypoxia. Mol Cancer Res 2008; 6(12): 1819-29.
-
(2008)
Mol Cancer Res
, vol.6
, Issue.12
, pp. 1819-1829
-
-
Zhao, D.1
Najbauer, J.2
Garcia, E.3
Metz, M.Z.4
Gutova, M.5
Glackin, C.A.6
-
119
-
-
77949514437
-
Neural stem cells as a novel platform for tumorspecific delivery of therapeutic antibodies
-
Frank RT, Edmiston M, Kendall SE, Najbauer J, Cheung CW, Kassa T, et al. Neural stem cells as a novel platform for tumorspecific delivery of therapeutic antibodies. PLoS One 2009; 4(12): e8314.
-
(2009)
PLoS One
, vol.4
, Issue.12
-
-
Frank, R.T.1
Edmiston, M.2
Kendall, S.E.3
Najbauer, J.4
Cheung, C.W.5
Kassa, T.6
-
120
-
-
61649103519
-
Human neural stem cells can target and deliver therapeutic genes to breast cancer brain metastases
-
Joo KM, Park IH, Shin JY, Jin J, Kang BG, Kim MH, et al. Human neural stem cells can target and deliver therapeutic genes to breast cancer brain metastases. Mol Ther 2009; 17(3): 570-5.
-
(2009)
Mol Ther
, vol.17
, Issue.3
, pp. 570-575
-
-
Joo, K.M.1
Park, I.H.2
Shin, J.Y.3
Jin, J.4
Kang, B.G.5
Kim, M.H.6
-
121
-
-
84862916213
-
Human neural stem cell tropism to metastatic breast cancer
-
Zhao D, Najbauer J, Annala AJ, Garcia E, Metz MZ, Gutova M, et al. Human neural stem cell tropism to metastatic breast cancer. Stem Cells 2012; 30(2): 314-25.
-
(2012)
Stem Cells
, vol.30
, Issue.2
, pp. 314-325
-
-
Zhao, D.1
Najbauer, J.2
Annala, A.J.3
Garcia, E.4
Metz, M.Z.5
Gutova, M.6
-
122
-
-
33846227546
-
Getting the right stuff: Controlling neural stem cell state and fate in vivo and in vitro with biomaterials
-
Teixeira AI, Duckworth JK, Hermanson O. Getting the right stuff: Controlling neural stem cell state and fate in vivo and in vitro with biomaterials. Cell Res 2007; 17(1): 56-61.
-
(2007)
Cell Res
, vol.17
, Issue.1
, pp. 56-61
-
-
Teixeira, A.I.1
Duckworth, J.K.2
Hermanson, O.3
-
123
-
-
46949107691
-
Mechanisms of disease: The role of stem cells in the biology and treatment of gliomas
-
Dietrich J, Imitola J, Kesari S. Mechanisms of disease: The role of stem cells in the biology and treatment of gliomas. Nat Clin Pract Oncol 2008; 5(7): 393-404.
-
(2008)
Nat Clin Pract Oncol
, vol.5
, Issue.7
, pp. 393-404
-
-
Dietrich, J.1
Imitola, J.2
Kesari, S.3
-
125
-
-
80455162612
-
Proteolytically stable cancer targeting peptides with high affinity for breast cancer cells
-
Soudy R, Gill A, Sprules T, Lavasanifar A, Kaur K. Proteolytically stable cancer targeting peptides with high affinity for breast cancer cells. J Med Chem 2011; 54(21): 7523-34.
-
(2011)
J Med Chem
, vol.54
, Issue.21
, pp. 7523-7534
-
-
Soudy, R.1
Gill, A.2
Sprules, T.3
Lavasanifar, A.4
Kaur, K.5
-
129
-
-
84875330758
-
-
US2011034169
-
Giangrande, P.H., Mcnamara, J.O., Thiel, K.W., Thiel, W., Rockey, W.M. HER2 nucleic acid aptamers. US2011034169 (2011).
-
(2011)
HER2 nucleic acid aptamers
-
-
Giangrande, P.H.1
McNamara, J.O.2
Thiel, K.W.3
Thiel, W.4
Rockey, W.M.5
-
130
-
-
58149240891
-
RNA aptamer blockade of osteopontin inhibits growth and metastasis of MDA-MB231 breast cancer cells
-
Mi Z, Guo H, Russell MB, Liu Y, Sullenger BA, Kuo PC. RNA aptamer blockade of osteopontin inhibits growth and metastasis of MDA-MB231 breast cancer cells. Mol Ther 2009; 17(1): 153-61.
-
(2009)
Mol Ther
, vol.17
, Issue.1
, pp. 153-161
-
-
Mi, Z.1
Guo, H.2
Russell, M.B.3
Liu, Y.4
Sullenger, B.A.5
Kuo, P.C.6
-
131
-
-
77958152852
-
Delivering cargoes into cancer cells using DNA aptamers targeting internalized surface portals
-
Orava EW, Cicmil N, Gariepy J. Delivering cargoes into cancer cells using DNA aptamers targeting internalized surface portals. Biochim Biophys Acta 2010; 1798(12): 2190-200.
-
(2010)
Biochim Biophys Acta
, vol.1798
, Issue.12
, pp. 2190-2200
-
-
Orava, E.W.1
Cicmil, N.2
Gariepy, J.3
-
135
-
-
0037133217
-
A peptide derived from alpha-fetoprotein prevents the growth of estrogen-dependent human breast cancers sensitive and resistant to tamoxifen
-
Bennett JA, Mesfin FB, Andersen TT, Gierthy JF, Jacobson HI. A peptide derived from alpha-fetoprotein prevents the growth of estrogen-dependent human breast cancers sensitive and resistant to tamoxifen. Proc Natl Acad Sci USA 2002; 99(4): 2211-5.
-
(2002)
Proc Natl Acad Sci USA
, vol.99
, Issue.4
, pp. 2211-2215
-
-
Bennett, J.A.1
Mesfin, F.B.2
Andersen, T.T.3
Gierthy, J.F.4
Jacobson, H.I.5
-
136
-
-
0034655853
-
Alphafetoprotein-derived antiestrotrophic octapeptide
-
Mesfin FB, Bennett JA, Jacobson HI, Zhu S, Andersen TT. Alphafetoprotein-derived antiestrotrophic octapeptide. Biochim Biophys Acta 2000; 1501(1): 33-43.
-
(2000)
Biochim Biophys Acta
, vol.1501
, Issue.1
, pp. 33-43
-
-
Mesfin, F.B.1
Bennett, J.A.2
Jacobson, H.I.3
Zhu, S.4
Andersen, T.T.5
-
137
-
-
84875304784
-
-
US20100249040
-
Andersen, T.T., Bennett, J.A., Jacobson, H.I., Mesfin, F.B. Alphafetoprotein peptides and uses thereof. US20100249040 (2010).
-
(2010)
Alphafetoprotein peptides and uses thereof
-
-
Andersen, T.T.1
Bennett, J.A.2
Jacobson, H.I.3
Mesfin, F.B.4
-
139
-
-
79961079796
-
Antiangiogenic antitumor activity of HPMA copolymerpaclitaxel-alendronate conjugate on breast cancer bone metastasis mouse model
-
Miller K, Eldar-Boock A, Polyak D, Segal E, Benayoun L, Shaked Y, et al. Antiangiogenic antitumor activity of HPMA copolymerpaclitaxel-alendronate conjugate on breast cancer bone metastasis mouse model. Mol Pharm 2011; 8(4): 1052-62.
-
(2011)
Mol Pharm
, vol.8
, Issue.4
, pp. 1052-1062
-
-
Miller, K.1
Eldar-Boock, A.2
Polyak, D.3
Segal, E.4
Benayoun, L.5
Shaked, Y.6
-
140
-
-
84865370343
-
Combination drug delivery approaches in metastatic breast cancer
-
Lee JH, Nan A. Combination drug delivery approaches in metastatic breast cancer. J Drug Deliv 2012; 2012: 915375.
-
(2012)
J Drug Deliv
, vol.2012
, pp. 915375
-
-
Lee, J.H.1
Nan, A.2
-
142
-
-
84875295580
-
-
US8263664
-
Kim, D., Gao, Z., Lee, E.S., Bae, Y.H. pH-sensitive polymeric micelles for drug delivery. US8263664 (2012).
-
(2012)
pH-sensitive polymeric micelles for drug delivery
-
-
Kim, D.1
Gao, Z.2
Lee, E.S.3
Bae, Y.H.4
-
143
-
-
79951847458
-
Polymalic acid-based nanobiopolymer provides efficient systemic breast cancer treatment by inhibiting both HER2/neu receptor synthesis and activity
-
Inoue S, Ding H, Portilla-Arias J, Hu J, Konda B, Fujita M, et al. Polymalic acid-based nanobiopolymer provides efficient systemic breast cancer treatment by inhibiting both HER2/neu receptor synthesis and activity. Cancer Res 2011; 71(4): 1454-64.
-
(2011)
Cancer Res
, vol.71
, Issue.4
, pp. 1454-1464
-
-
Inoue, S.1
Ding, H.2
Portilla-Arias, J.3
Hu, J.4
Konda, B.5
Fujita, M.6
-
144
-
-
84857089600
-
Nanobiopolymer for direct targeting and inhibition of EGFR expression in triple negative breast cancer
-
Inoue S, Patil R, Portilla-Arias J, Ding H, Konda B, Espinoza A, et al. Nanobiopolymer for direct targeting and inhibition of EGFR expression in triple negative breast cancer. PLoS One 2012; 7(2): e31070.
-
(2012)
PLoS One
, vol.7
, Issue.2
-
-
Inoue, S.1
Patil, R.2
Portilla-Arias, J.3
Ding, H.4
Konda, B.5
Espinoza, A.6
-
145
-
-
77957942614
-
A strategy for precision engineering of nanoparticles of biodegradable copolymers for quantitative control of targeted drug delivery
-
Liu Y, Li K, Liu B, Feng SS. A strategy for precision engineering of nanoparticles of biodegradable copolymers for quantitative control of targeted drug delivery. Biomaterials 2010; 31(35): 9145-55.
-
(2010)
Biomaterials
, vol.31
, Issue.35
, pp. 9145-9155
-
-
Liu, Y.1
Li, K.2
Liu, B.3
Feng, S.S.4
-
148
-
-
51449104994
-
A novel nanoparticle formulation for sustained paclitaxel delivery
-
Trickler WJ, Nagvekar AA, Dash AK. A novel nanoparticle formulation for sustained paclitaxel delivery. AAPS PharmSciTech 2008; 9(2): 486-93.
-
(2008)
AAPS PharmSciTech
, vol.9
, Issue.2
, pp. 486-493
-
-
Trickler, W.J.1
Nagvekar, A.A.2
Dash, A.K.3
-
149
-
-
33847155509
-
Nanoparticle-mediated drug delivery and gene therapy
-
Jin S, Ye K. Nanoparticle-mediated drug delivery and gene therapy. Biotechnol Prog 2007; 23(1): 32-41.
-
(2007)
Biotechnol Prog
, vol.23
, Issue.1
, pp. 32-41
-
-
Jin, S.1
Ye, K.2
-
150
-
-
77957065782
-
Towards a targeted multi-drug delivery approach to improve therapeutic efficacy in breast cancer
-
Wang B, Rosano JM, Cheheltani R, Achary MP, Kiani MF. Towards a targeted multi-drug delivery approach to improve therapeutic efficacy in breast cancer. Expert Opin Drug Deliv 2010; 7(10): 1159-73.
-
(2010)
Expert Opin Drug Deliv
, vol.7
, Issue.10
, pp. 1159-1173
-
-
Wang, B.1
Rosano, J.M.2
Cheheltani, R.3
Achary, M.P.4
Kiani, M.F.5
-
151
-
-
77954645526
-
The use of nanocarriers for drug delivery in cancer therapy
-
Khan DR. The use of nanocarriers for drug delivery in cancer therapy. J Cancer Sci Ther 2010; 2(3): 58-62.
-
(2010)
J Cancer Sci Ther
, vol.2
, Issue.3
, pp. 58-62
-
-
Khan, D.R.1
-
152
-
-
79960925147
-
Targeted drug delivery to tumors: Myths, reality and possibility
-
Bae YH, Park K. Targeted drug delivery to tumors: Myths, reality and possibility. J Control Release 2011; 153(3): 198-205.
-
(2011)
J Control Release
, vol.153
, Issue.3
, pp. 198-205
-
-
Bae, Y.H.1
Park, K.2
-
153
-
-
84862505006
-
The ubiquitin-like protein, ISG15, is a novel tumor-associated antigen for cancer immunotherapy
-
Wood LM, Pan ZK, Seavey MM, Muthukumaran G, Paterson Y. The ubiquitin-like protein, ISG15, is a novel tumor-associated antigen for cancer immunotherapy. Cancer Immunol Immunother 2012; 61(5): 689-700.
-
(2012)
Cancer Immunol Immunother
, vol.61
, Issue.5
, pp. 689-700
-
-
Wood, L.M.1
Pan, Z.K.2
Seavey, M.M.3
Muthukumaran, G.4
Paterson, Y.5
-
154
-
-
79953190024
-
IL-12 enhances the antitumor actions of trastuzumab via NK cell IFN-gamma production
-
Jaime-Ramirez AC, Mundy-Bosse BL, Kondadasula S, Jones NB, Roda JM, Mani A, et al. IL-12 enhances the antitumor actions of trastuzumab via NK cell IFN-gamma production. J Immunol 2011; 186(6): 3401-9.
-
(2011)
J Immunol
, vol.186
, Issue.6
, pp. 3401-3409
-
-
Jaime-Ramirez, A.C.1
Mundy-Bosse, B.L.2
Kondadasula, S.3
Jones, N.B.4
Roda, J.M.5
Mani, A.6
-
155
-
-
77955656948
-
Intratumoral delivery of encapsulated IL-12, IL-18 and TNF-alpha in a model of metastatic breast cancer
-
Sabel MS, Su G, Griffith KA, Chang AE. Intratumoral delivery of encapsulated IL-12, IL-18 and TNF-alpha in a model of metastatic breast cancer. Breast Cancer Res Treat 2010; 122(2): 325-36.
-
(2010)
Breast Cancer Res Treat
, vol.122
, Issue.2
, pp. 325-336
-
-
Sabel, M.S.1
Su, G.2
Griffith, K.A.3
Chang, A.E.4
-
157
-
-
79751472667
-
Tumor-derived JAGGED1 promotes osteolytic bone metastasis of breast cancer by engaging notch signaling in bone cells
-
Sethi N, Dai X, Winter CG, Kang Y. Tumor-derived JAGGED1 promotes osteolytic bone metastasis of breast cancer by engaging notch signaling in bone cells. Cancer Cell 2011; 19(2): 192-205.
-
(2011)
Cancer Cell
, vol.19
, Issue.2
, pp. 192-205
-
-
Sethi, N.1
Dai, X.2
Winter, C.G.3
Kang, Y.4
-
158
-
-
77955377644
-
Interference with Sin3 function induces epigenetic reprogramming and differentiation in breast cancer cells
-
Farias EF, Petrie K, Leibovitch B, Murtagh J, Chornet MB, Schenk T, et al. Interference with Sin3 function induces epigenetic reprogramming and differentiation in breast cancer cells. Proc Natl Acad Sci USA 2010; 107(26): 11811-6.
-
(2010)
Proc Natl Acad Sci USA
, vol.107
, Issue.26
, pp. 11811-11816
-
-
Farias, E.F.1
Petrie, K.2
Leibovitch, B.3
Murtagh, J.4
Chornet, M.B.5
Schenk, T.6
-
160
-
-
84864911902
-
AMD3100-mediated production of interleukin-1 from mesenchymal stem cells is key to chemosensitivity of breast cancer cells
-
Greco SJ, Patel SA, Bryan M, Pliner LF, Banerjee D, Rameshwar P. AMD3100-mediated production of interleukin-1 from mesenchymal stem cells is key to chemosensitivity of breast cancer cells. Am J Cancer Res 2011; 1(6): 701-15.
-
(2011)
Am J Cancer Res
, vol.1
, Issue.6
, pp. 701-715
-
-
Greco, S.J.1
Patel, S.A.2
Bryan, M.3
Pliner, L.F.4
Banerjee, D.5
Rameshwar, P.6
-
162
-
-
84866481797
-
Mesenchymal stem cell-derived interleukin-6 and vascular endothelial growth factor promote breast cancer cell migration
-
De Luca A, Lamura L, Gallo M, Maffia V, Normanno N. Mesenchymal stem cell-derived interleukin-6 and vascular endothelial growth factor promote breast cancer cell migration. J Cell Biochem 2012; 113(11): 3363-70.
-
(2012)
J Cell Biochem
, vol.113
, Issue.11
, pp. 3363-3370
-
-
de Luca, A.1
Lamura, L.2
Gallo, M.3
Maffia, V.4
Normanno, N.5
-
163
-
-
84856285214
-
Enhancing intracellular taxane delivery: Current role and perspectives of nanoparticle albuminbound paclitaxel in the treatment of advanced breast cancer
-
Guarneri V, Dieci MV, Conte P. Enhancing intracellular taxane delivery: Current role and perspectives of nanoparticle albuminbound paclitaxel in the treatment of advanced breast cancer. Expert Opin Pharmacother 2012; 13(3): 395-406.
-
(2012)
Expert Opin Pharmacother
, vol.13
, Issue.3
, pp. 395-406
-
-
Guarneri, V.1
Dieci, M.V.2
Conte, P.3
-
164
-
-
20444400599
-
Paclitaxel resistance in cells with reduced betatubulin
-
Wang Y, Cabral F. Paclitaxel resistance in cells with reduced betatubulin. Biochim Biophys Acta 2005; 1744(2): 245-55.
-
(2005)
Biochim Biophys Acta
, vol.1744
, Issue.2
, pp. 245-255
-
-
Wang, Y.1
Cabral, F.2
-
165
-
-
84873496961
-
Non-invasive imaging of PI3K/Akt/mTOR signalling in cancer
-
Gaikwad SM, Ray P. Non-invasive imaging of PI3K/Akt/mTOR signalling in cancer. Am J Nucl Med Mol Imaging 2012; 2(4): 418-31.
-
(2012)
Am J Nucl Med Mol Imaging
, vol.2
, Issue.4
, pp. 418-431
-
-
Gaikwad, S.M.1
Ray, P.2
-
166
-
-
38649085317
-
Fibronectin-mediated activation of Akt2 protects human ovarian and breast cancer cells from docetaxel-induced apoptosis via inhibition of the p38 pathway
-
Xing H, Cao Y, Weng D, Tao W, Song X, Wang W, et al. Fibronectin-mediated activation of Akt2 protects human ovarian and breast cancer cells from docetaxel-induced apoptosis via inhibition of the p38 pathway. Apoptosis 2008; 13(2): 213-23.
-
(2008)
Apoptosis
, vol.13
, Issue.2
, pp. 213-223
-
-
Xing, H.1
Cao, Y.2
Weng, D.3
Tao, W.4
Song, X.5
Wang, W.6
-
167
-
-
0035807219
-
Inhibition of BRCA1 leads to increased chemoresistance to microtubule-interfering agents, an effect that involves the JNK pathway
-
Lafarge S, Sylvain V, Ferrara M, Bignon YJ. Inhibition of BRCA1 leads to increased chemoresistance to microtubule-interfering agents, an effect that involves the JNK pathway. Oncogene 2001; 20(45): 6597-606.
-
(2001)
Oncogene
, vol.20
, Issue.45
, pp. 6597-6606
-
-
Lafarge, S.1
Sylvain, V.2
Ferrara, M.3
Bignon, Y.J.4
-
168
-
-
38449113305
-
Integrin-mediated adhesion: Tipping the balance between chemosensitivity and chemoresistance
-
Zutter MM. Integrin-mediated adhesion: Tipping the balance between chemosensitivity and chemoresistance. Adv Exp Med Biol 2007; 608: 87-100.
-
(2007)
Adv Exp Med Biol
, vol.608
, pp. 87-100
-
-
Zutter, M.M.1
-
169
-
-
84863625224
-
A CXCL1 paracrine network links cancer chemoresistance and metastasis
-
Acharyya S, Oskarsson T, Vanharanta S, Malladi S, Kim J, Morris PG, et al. A CXCL1 paracrine network links cancer chemoresistance and metastasis. Cell 2012; 150(1): 165-78.
-
(2012)
Cell
, vol.150
, Issue.1
, pp. 165-178
-
-
Acharyya, S.1
Oskarsson, T.2
Vanharanta, S.3
Malladi, S.4
Kim, J.5
Morris, P.G.6
-
171
-
-
84875289588
-
-
US20110313229
-
Sugaya, K., Alvarez, A., Bushnev, S., Avgeropoulos, N.G. Therapy targeting cancer stem cells. US20110313229 (2011).
-
(2011)
Therapy targeting cancer stem cells
-
-
Sugaya, K.1
Alvarez, A.2
Bushnev, S.3
Avgeropoulos, N.G.4
-
173
-
-
0035845511
-
Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications
-
Sorlie T, Perou CM, Tibshirani R, Aas T, Geisler S, Johnsen H, et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA 2001; 98(19): 10869-74.
-
(2001)
Proc Natl Acad Sci USA
, vol.98
, Issue.19
, pp. 10869-10874
-
-
Sorlie, T.1
Perou, C.M.2
Tibshirani, R.3
Aas, T.4
Geisler, S.5
Johnsen, H.6
-
174
-
-
84861708138
-
Molecular biology in breast cancer: Intrinsic subtypes and signaling pathways
-
Eroles P, Bosch A, Perez-Fidalgo JA, Lluch A. Molecular biology in breast cancer: Intrinsic subtypes and signaling pathways. Cancer Treat Rev 2012; 38(6): 698-707.
-
(2012)
Cancer Treat Rev
, vol.38
, Issue.6
, pp. 698-707
-
-
Eroles, P.1
Bosch, A.2
Perez-Fidalgo, J.A.3
Lluch, A.4
-
175
-
-
83455236666
-
Basal breast cancer: A complex and deadly molecular subtype
-
Bertucci F, Finetti P, Birnbaum D. Basal breast cancer: A complex and deadly molecular subtype. Curr Mol Med 2012; 12(1): 96-110.
-
(2012)
Curr Mol Med
, vol.12
, Issue.1
, pp. 96-110
-
-
Bertucci, F.1
Finetti, P.2
Birnbaum, D.3
-
176
-
-
84861987023
-
Prognostic value of basal phenotype in HER2-overexpressing breast cancer
-
Bagaria SP, Ray PS, Wang J, Kropcho L, Chung A, Sim MS, et al. Prognostic value of basal phenotype in HER2-overexpressing breast cancer. Ann Surg Oncol 2012; 19(3): 935-40.
-
(2012)
Ann Surg Oncol
, vol.19
, Issue.3
, pp. 935-940
-
-
Bagaria, S.P.1
Ray, P.S.2
Wang, J.3
Kropcho, L.4
Chung, A.5
Sim, M.S.6
-
177
-
-
84855291245
-
Luminal-B breast cancer and novel therapeutic targets
-
Tran B, Bedard PL. Luminal-B breast cancer and novel therapeutic targets. Breast Cancer Res 2011; 13(6): 221.
-
(2011)
Breast Cancer Res
, vol.13
, Issue.6
, pp. 221
-
-
Tran, B.1
Bedard, P.L.2
-
178
-
-
83755174643
-
Molecular classification of estrogen receptor-positive/luminal breast cancers
-
Geyer FC, Rodrigues DN, Weigelt B, Reis-Filho JS. Molecular classification of estrogen receptor-positive/luminal breast cancers. Adv Anat Pathol 2012; 19(1): 39-53.
-
(2012)
Adv Anat Pathol
, vol.19
, Issue.1
, pp. 39-53
-
-
Geyer, F.C.1
Rodrigues, D.N.2
Weigelt, B.3
Reis-Filho, J.S.4
-
179
-
-
84855811750
-
Targeting the subtypes of breast cancer: Rethinking investigational drugs
-
Curigliano G, Locatelli M, Fumagalli L, Brollo J, Munzone E, Nole F, et al. Targeting the subtypes of breast cancer: Rethinking investigational drugs. Expert Opin Investig Drugs 2012; 21(2): 191-204.
-
(2012)
Expert Opin Investig Drugs
, vol.21
, Issue.2
, pp. 191-204
-
-
Curigliano, G.1
Locatelli, M.2
Fumagalli, L.3
Brollo, J.4
Munzone, E.5
Nole, F.6
-
180
-
-
84872500139
-
Subtype-specific response to bevacizumab is reflected in the metabolome and transcriptome of breast cancer xenografts
-
Borgan E, Lindholm EM, Moestue S, Maelandsmo GM, Lingjaerde OC, Gribbestad IS, et al. Subtype-specific response to bevacizumab is reflected in the metabolome and transcriptome of breast cancer xenografts. Mol Oncol 2012; 7(1): 130-42.
-
(2012)
Mol Oncol
, vol.7
, Issue.1
, pp. 130-142
-
-
Borgan, E.1
Lindholm, E.M.2
Moestue, S.3
Maelandsmo, G.M.4
Lingjaerde, O.C.5
Gribbestad, I.S.6
|